Sanofi

News

Sanofi has bolstered its rare disease business with an agreement to buy Blueprint Medicines and blockbuster-in-waiting Ayvakit for ASM.

News

Despite a voluntary admission of a breach of the ABPI code, Sanofi is deemed to have "brought discredit" on the pharma industry.

Patients

In a new pharmaphorum podcast, Rebecca Catterick, previously at Sanofi, discusses the decline in vaccination rates.

News

GSK gets FDA approval for Nucala in COPD, setting up a marketing tussle with Sanofi/Regeneron's Dupixent.

News

Sanofi bids to add a drug candidate for Alzheimer's disease to its neurology pipeline via the acquisition of US biotech Vigil Neuroscience.

News

Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in the US.